Objectives: To find out whether routine use of erythropoietin (EPO) would reduce transfusion requirements in infants <1.5 kg and/or <32 weeks at birth and compare haemoglobin and reticulocyte counts of EPO treated and untreated groups.
Introduction
Neonatology is a growing subspecialty in Sri Lanka and a large number of extremely premature/very low birth weight babies are being managed in neonatal intensive care units (NICUs) all over the country. Extremely low birth weight (ELBW) infants are exposed to frequent drawing of blood. These infants develop anaemia of prematurity (AOP), additionally by inadequate production of erythropoietin (EPO). Treatment of AOP includes _______________________________________ 1 Acting Consultant Neonatologist Teaching Hospital, Kandy, 2 Consultant Neonatologist, Sri Jayewardenepura General Hospital, Kotte (Received on 26 November 2010: Accepted on 17 January 2011) red blood cell transfusions, which are given to preterm infants based on indications 1 .
Transfused infants generally receive several packed cell transfusions during their hospital stay. Transfusions are given as and when required by low haemoglobin (Hb) and the practice of single donor transfusion is not possible in most centres; babies are exposed to different donor samples and hence multiple sensitisations, in addition to the related risk of infection.
Anaemia of the premature baby is known to be contributed to by the lack of EPO to a larger extent rather than by deficiency of raw material needed for erythropoiesis 2 . EPO is an accepted mode of treatment for anaemia associated with extreme prematurity 3, 4 but there is no strong evidence to support or reject the routine administration of erythropoietin in AOP 5 . We designed this study to see whether this practice is suitable to our country.
Objectives

1.
To find out whether the routine use of EPO in the first two weeks of life would reduce the transfusion requirement of babies with birth weights <1500g and/or gestational age less than 32 weeks 2. To compare the Hb and reticulocyte counts of the EPO treated group with the untreated group.
Method
A prospective case control study was carried out on infants born at Sri Jayewardenepura General Hospital (SJGH) from 1 st November 2006 to 31 st October 2007 with birth weights <1500g and/or gestational age <32 weeks in whom maternal consent was obtained. Babies with major congenital malformations, chromosomal anomalies, haemolytic disease, haemorrhagic disease, intrauterine infections and systemic hypertension were excluded from the study. Infants were allocated randomly to treatment and control groups according to last 2 digits of the admission register.
The treatment group (cases) received EPO (300 units/kg/day, thrice weekly, subcutaneously) during first 14 days of life, starting before 72 hours of birth. All infants (cases and controls) were given oral iron (6 mg/kg/day, as ferrous sulphate) 6 and folic acid (2 mg/day) starting when enteral feeding was initiated and continuing during the entire treatment period. Indications for transfusions followed a set of transfusion criteria laid down by authors after a lengthy literature review 7 (Table 1) and the same criteria were used as a unit protocol. Patients were transfused with packed red blood cells at 20 ml/kg, administered over 3 to 4 hours. Respiratory rate, heart rate, blood pressure, number of apnoeic episodes, weight gain, and neurologic status were recorded daily. Total volume of blood withdrawn and the number and volume of blood transfusions were recorded daily from birth to 8 weeks. Laboratory monitoring included full blood count with reticulocyte and platelet counts twice weekly and weekly liver and renal function tests. All infants were followed up for at least 6 months after discharge from the hospital. The trial was approved by ethics and medical education committees of the Sri Jayewardenepura General Hospital. Parents gave written informed consent before entering infants into the protocol. Data was analyzed by stat direct software using student T test.
Results
During the study period the total number of babies born at SJGH with birth weights <1500g and/or gestational age <32 weeks was 106. Seven patients (1 chromosomal abnormality, 1 major congenital malformation, 1 haemorrhagic disease and 3 haemolytic disease) were excluded from the study. Of the 99 babies eligible for enrolment maternal consent was obtained in 88. Two babies were voluntarily taken out of study by the mothers. Eight babies died before completing the study (4 died of respiratory distress associated with extreme prematurity, 2 died of sepsis, 2 died of perinatal asphyxia). Seventy eight infants remained available for the final analysis. The characteristics of the 78 study infants are shown in Table 2 . 5%) The volume of phlebotomy losses and transfusion requirement throughout the study were analysed. There was no statistically significant difference between infants who received EPO and the control group (Table 3) . All transfusions administered met transfusion criteria. The total transfusion requirement was the same for both groups. No differences in the number of infants transfused, number of transfusions per infant, or volume of packed erythrocytes transfused between groups could be demonstrated. The total transfusion requirements were 4.4 ± 1.7 and 6.4 ± 3.5 transfusions per infant for the cases and controls respectively. Figure 1 shows the variation of haematological values during the first 8 weeks of age.
EPO treated group acquired high reticulocyte count earlier than control group with maximal transient difference in the second week (Table 4 ) but by 8 weeks the gap was narrowed. There was no overall statistically significant difference in reticulocyte count between cases and controls. Hb values showed a gradual decline in both cases and controls. Hb values in cases were always high but the difference was not statistically significant. (Table 5 ) Oral iron administration was started at 9.4 ± 3.0 days in the cases and at 9.3 ± 2.7 days in the control group. The infants in the 2 groups had equivalent caloric intakes and rates of growth. The weight gain during the study was similar for both groups ( Table 6 ). The mean weights at the end of treatment were 1263 ± 204 g and 1171 ± 192 g respectively. 
Discussion
There is a high level of erythropoiesis in the growing fetus 8 . In utero relative hypoxia results in a relatively high haematocrit and predominant synthesis of HbF, with EPO produced in the liver regulating erythropoiesis. At birth fetal EPO concentration is high but declines progressively thereafter. In preterm infants the expected postnatal decline in Hb is more prolonged and pronounced than in full-term infants and the premature infants may become anaemic. Some studies have shown that EPO given to infants with anaemia of prematurity produced an earlier increase in reticulocyte counts compared with placebo; however, the difference between groups was not significant 9 . EPO therapy did not suppress subsequent release of endogenous EPO. It is suggested that a higher dose of EPO may be required to treat anaemic premature infants 10 .
Very low birth weight (VLBW) infants are one of the main groups of patients requiring red blood cell transfusions. Sixty percent to 100% of VLBW infants receive multiple transfusions, mostly during the first 2 weeks of life 10 . The combination of EPO and oral iron stimulates erythropoiesis in preterm infants resulting in fewer transfusions during their early weeks of life 3 . The use of EPO during this period, when anaemia results predominantly from the amount of blood sampled for laboratory tests, has not been adequately evaluated. A few published trials have suggested its usefulness, but the interpretation of these results remains controversial 11 . There is limited data available on EPO and oral iron in the very early neonatal period as well as the bone marrow response 12 .
In our study, the EPO administration was associated with higher reticulocyte counts and haematocrits compared with controls. However, this response was not sufficient to decrease the need for transfusion; the number of transfusions received as well as the total transfusion requirement was similar for both groups. However, EPO can be used as a mode of treatment in selected cases e.g. Jehovah witness 13 . In these cases low transfusion requirement can be achieved by combination of several methods: 1) use of EPO 2) adherence to very strict transfusion criteria 3) minimising the number of routine blood tests and 4) early iron treatment.
We started oral iron and folic acid as soon as enteral feedings were initiated 14 . There were no clinical adverse effects to iron administration. Therefore, we believe that our protocol for early oral haematinic supplementation is adequate to support a response to EPO. Some reports suggest that rarely thrombocytopenia and neutropenia could occur with EPO 15 but this was not a feature in our study.
Conclusion
There is no benefit from routine administration of EPO to preterm infants during the first two weeks of life in preventing anaemia of prematurity.
